Bioheart, Inc. announced that Ms. Evelyn Flores will join Bioheart as Corporate Controller. A tenured finance and accounting executive, Ms. Flores has over 15 years of public and private company experience in tax and audit preparation, SOX narratives, matrix preparation and SEC filings. Ms. Flores earned a BS in Accounting and Finance from the University of Illinois and an MBA in Accounting and Finance from Nova Southeastern University.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
2023 | U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2023 | U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 661 | |
+16.76% | 12TCr | |
+19.79% | 12TCr | |
+21.22% | 2.66TCr | |
-23.23% | 1.99TCr | |
-17.47% | 1.63TCr | |
-45.95% | 1.55TCr | |
-18.71% | 1.55TCr | |
+61.52% | 1.48TCr | |
+3.55% | 1.37TCr |
- Stock Market
- Equities
- USRM Stock
- News U.S. Stem Cell, Inc.
- Bioheart, Inc. Appoints Evelyn Flores as Corporate Controller